文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

MRI引导局灶高剂量率近距离放疗治疗局限性前列腺癌:毒性、生化结局与生活质量

MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
PubMed 文献 · Radiother Oncol · 2018-08-18

单中心研究纳入30例局限性前列腺癌患者,接受MRI引导局灶高剂量率近距离放疗单次19 Gy。中位随访24个月,1例发生2级和3级泌尿生殖毒性,5例出现生化复发,各时间点生活质量无统计学显著下降。作者认为毒性低且维持生活质量,但生化复发率较高,需更长期评估并谨慎实施。

要点

  • MRI引导局灶HDR-BT单次19 Gy,30例中仅1例发生2级和3级泌尿生殖毒性。
  • 中位随访24个月,5例按Phoenix标准出现生化复发。
  • 所有测量时间点生活质量无统计学显著下降。

核心结论

  • 作者结论认为MRI引导局灶HDR-BT毒性低并维持生活质量,但生化复发率较高,需更长期评估并谨慎实施。

研究设计与样本

  • 单中心研究,2013年5月至2016年4月纳入30例MRI可见肿瘤的局限性前列腺癌患者。
  • 患者均≥65岁、T分期<T3、Gleason≤7、PSA<10 ng/mL且IPSS<15。
  • 局灶照射为单次19 Gy,处方至临床靶区D95。
  • 毒性按常见不良事件评价标准第4版报告,生化失败按Phoenix标准定义,生活质量采用经验证问卷测量。

主要发现

  • 中位随访24个月。
  • 1例治疗后发生2级和3级泌尿生殖毒性,其余29例无2级及以上围手术期并发症。
  • 5例出现生化复发。
  • 所有测量时间点生活质量无统计学显著下降。

关键数值与推荐

  • 生化失败按Phoenix标准定义。
  • 毒性分级采用常见不良事件评价标准第4版。

临床怎么用

  • 作者认为局灶HDR-BT毒性低并维持生活质量,但生化复发率较高,需更长期评估,在局限性前列腺癌患者中实施前应谨慎。

局限性

  • 作者指出需更长期评估这些患者,并在实施局灶HDR-BT前应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe toxicity, biochemical outcome and quality of life after MRI guided focal high dose rate brachytherapy (HDR-BT) in a single fraction of 19 Gy for localized prostate cancer. MATERIALS AND METHODS: Between May 2013 and April 2016, 30 patients were treated by MRI-guided focal HDR-BT. Patients with visible tumour on MRI were included. All patients were ≥65 years, T-stage <T3, Gleason ≤7, PSA <10 ng/mL and IPSS <15. Focal irradiation was delivered in a single fraction of 19 Gy to the D95 of the clinical target volume. Toxicity was reported using the Common Terminology Criteria for Adverse Events version 4. Biochemical failure was defined according to the Phoenix criteria and quality of life was measured using validated questionnaires. RESULTS: Median follow up was 24 months. One patient developed a grade 2 and 3 GU toxicity after treatment. In the other 29 patients, no grade 2 or higher perioperative complications occurred. Five patients developed a biochemical recurrence. For all measured time points, there was no statistically significant deterioration in quality of life. CONCLUSION: Focal MRI guided HDR-BT confers low toxicity rates and maintains quality of life. Biochemical recurrence is rather high, 5 patients developed a biochemical recurrence according to the Phoenix definition. Longer evaluation of these patients is necessary and caution is warranted before implementing focal HDR-BT in patients with localized prostate cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Maenhout M, Peters M, Moerland MA, et al. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Radiother Oncol. 2018. PMID: 30131183. doi:10.1016/j.radonc.2018.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。